Ignite Creation Date:
2025-12-24 @ 11:50 PM
Ignite Modification Date:
2026-01-06 @ 10:11 PM
Study NCT ID:
NCT04876651
Status:
RECRUITING
Last Update Posted:
2024-05-31
First Post:
2021-05-03
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
The Present Study Aims to Compare Patients Who Receive the Investigational Product (177Lu-DOTA-rosopatamab) Plus Standard of Care, in Comparison to Standard of Care Only
Sponsor:
Telix Pharmaceuticals (Innovations) Pty Ltd
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
177Lu-TLX591-002
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None